Cardiovascular-Kidney-Metabolic Syndrome May Shorten Your Life Expectancy, reveals research

As chronic diseases continue to rise globally, this research offers timely evidence for healthcare providers, policymakers, and the public. The study shows that CKM syndrome, newly defined by the American Heart Association in 2023, is not just a medical concept but a real-world predictor of life expectancy and health outcomes. The findings support a shift toward cross-speciality collaboration in medicine, with particular relevance for aging populations, health insurers, and those shaping chronic disease policy.

Every Added Condition Matters: New Patterns Reveal Deadly Toll of CKM Syndrome

The study uncovered several significant patterns that clarify how CKM syndrome and its components influence long-term health risks:

• Widespread Impact: Over 70% of the study’s participants met the criteria for CKM syndrome. Among adults aged 55 and older, nearly 90% were affected.

• Increased Risk of Death: People with CKM syndrome had a 33% higher risk of death from any cause and were nearly three times more likely to die from cardiovascular disease.

• Kidney Disease Link: Those with CKM syndrome were over ten times more likely to develop end-stage kidney disease (ESKD), requiring dialysis or transplantation.

• Each Added Condition Matters: Every additional CKM component (such as hypertension, diabetes, chronic kidney disease, metabolic syndrome, or high triglyceride) increased the risk of all-cause death by 22% and cardiovascular death by 37%.

• Shorter Life Expectancy: Each additional component reduced life expectancy by approximately 2.5 years for men and 3 years for women. Those with all five components could lose up to 13–16 years of life.

Massive 25-Year Study Confirms CKM’s Deadly Impact in Over Half a Million Adults

Researchers from Taipei Medical University and collaborating institutions analyzed medical data from over 515,000 adults in Taiwan, collected between 1996 and 2017. Participants underwent physical exams, laboratory tests, and completed lifestyle questionnaires. The study tracked deaths and disease progression over 25 years, using statistical models to assess the impact of CKM components on mortality. The team used standardized definitions aligned with American Heart Association guidelines, which were adjusted for use in Asian populations.

“Our findings show that cardiovascular, kidney, and metabolic conditions are not isolated challenges-they are profoundly interconnected. We need a healthcare model that reflects the reality of how these diseases cluster and amplify risk, especially as populations age,” said Prof. Mai-Szu Wu and Prof. Mei-Yi Wu, the corresponding authors of the study.

First Large-Scale Asian Study Urges Shift to Integrated Chronic Disease Care

This study, published in PLOS Medicine in June 2025, is among the first large-scale evaluations of CKM syndrome in an Asian population, reinforcing the need for coordinated, multidisciplinary care. Treating high blood pressure, diabetes, or kidney disease in isolation may miss the broader picture-where the intersection of these conditions drives worse health outcomes. Early intervention and integrated disease management could help millions live longer and healthier lives.

Reference:

Min-Kuang Tsai,Juliana Tze-Wah Kao,Chung-Shun Wong,Chia-Te Liao,Wei-Cheng Lo,Kuo-Liong Chien,Chi-Pang Wen, Cardiovascular–kidney–metabolic syndrome and all-cause and cardiovascular mortality: A retrospective cohort study, PLOS Medicine, https://doi.org/10.1371/journal.pmed.1004629